OncRef

Clinical Trial: NCT02999477

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Adrienne G. Waks
Information Provided By:Dana-Farber Cancer Institute
Last Update Posted:2026-01-29

Study Overview

Brief Summary

This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for hormone receptor positive breast cancer.

The interventions involved in this study are:

  • Pembrolizumab (MK-3475; Keytruda™)
  • Nab-Paclitaxel (Abraxane

Official Title

A Pilot Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Conditions

Breast Cancer

Intervention / Treatment

  • Drug: Pembrolizumab
  • Drug: Nab-Paclitaxel
  • Procedure: Biopsy

Other Study ID Numbers

  • 16-466

Start Date (Actual)

2017-02-23

Primary Completion Date (Actual)

2022-11-20

Study Completion Date (Actual)

2026-01-08

Enrollment (Actual)

32

Study Type

Interventional

Phase

Phase 1